Loading...
•
Apr 03, 2021
Haemonetics Q4 2021 Earnings Report
Haemonetics' Q4 2021 financial results were reported, showing a decrease in revenue compared to the previous year, impacted by the COVID-19 pandemic but partially offset by cost mitigation efforts and the Operational Excellence Program.
Key Takeaways
Haemonetics reported a decrease in Q4 revenue by 5.6% to $225 million, primarily driven by the continued impact of COVID-19. The company experienced an operating loss of $21.2 million, and a net loss of $11.0 million, or $0.22 per share. Adjusted earnings per diluted share were $0.46. The company issued its FY2022 revenue growth guidance of 13–18%.
Q4 revenue decreased by 5.6% to $225 million due to the continued impact of COVID-19.
Operating loss was $21.2 million, compared to an operating income of $26.0 million in the prior year.
Net loss was $11.0 million, or $0.22 per share, compared to a net income of $17.6 million, or $0.34 per share in the prior year.
Adjusted earnings per diluted share were $0.46, down 33.3% compared to the prior year.
Haemonetics
Haemonetics
Haemonetics Revenue by Segment
Revenue by Segment
Plasma Revenue
CapyFin.comBlood Center Revenue
CapyFin.comHospital Revenue
CapyFin.com Forward Guidance
The Company issued its GAAP total revenue growth guidance of 13 – 18% and organic revenue growth guidance as follows: Organic1Total revenue8 - 12%Plasma revenue15 - 25%Hospital Revenue15 - 20%Blood Center revenue(6 - 8%)
Positive Outlook
- Total company GAAP revenue guidance includes $65 - $75 million revenue related to our Cardiva Medical Vascular Closure devices.
- Hospital organic revenue guidance includes a Hemostasis Management organic revenue growth in the mid-twenties.
- Adjusted operating margin19 - 20%
- Adjusted earnings per diluted share$2.60 - $3.00
- Free cash flow, before restructuring & turnaround$135M - $155M
Revenue & Expenses
Visualization of income flow from segment revenue to net income